Beta‐blockers and epithelial ovarian cancer survival: A Norwegian population‐based cohort study
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35348 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Leif Lukas Löfling und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Norges Forskningsråd.
Abstract (Originalsprache)
Cancer diagnosis and therapy cause stress to the body. Preclinical studies have shown that stress hormones can stimulate tumor progression and metastasis by interacting with β‐adrenergic receptors, and that β‐blockers can inhibit those processes. We assessed if β‐blocker use was associated with survival in a nationwide cohort of women with epithelial ovarian cancer (EOC). We identified all women aged ≥40 years who underwent EOC surgery in 2004–2018 in Norway through the Cancer Registry of Norway. We estimated the association between peri‐diagnostic and post‐diagnostic β‐blocker use and survival. We used Cox models, adjusted for sociodemographic and health factors, and reported hazard ratios (HRs) and 95% confidence intervals (CIs). The difference in overall survival time between β‐blocker users and non‐users was estimated as the difference in restricted mean survival time at 5 years after diagnosis using flexible parametric models. We included 3911 women with EOC; 540 (14%) used β‐blockers at diagnosis, 1672 (43%) died of the disease, and 1882 (48%) died overall. We found an association between peri‐diagnostic β‐blocker use and longer EOC‐specific survival (HR = 0.85, 95%CI 0.73–1.00; p‐value = 0.048), and an indication of an association with overall survival (HR = 0.89, 95%CI 0.77–1.02; p‐value = 0.101). Analysis of post‐diagnostic β‐blocker use, which included only women who survived 12 months or longer ( n = 3344), found similar associations. At 5 years from diagnosis, peri‐diagnostic β‐blocker users lived on average 1.28 months longer than non‐users (95%CI 0.01–2.60 months). The results support the hypothesis that β‐blocker use improves EOC‐specific survival in women with EOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
- Section for Epidemiology, Norwegian Veterinary Institute, Ås, Norway.
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Science, Monash University, Parkville, Victoria, Australia.
- Section for Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
ORCID-Profile: Leif Lukas Löfling, Sara Nafisi, Edoardo Botteri
Förderung
- Norges Forskningsråd
Zitieren
APA
Löfling, L. L., Støer, N. C., Sloan, E. K., Nafisi, S., Fortner, R. T., & Botteri, E. (2025). Beta‐blockers and epithelial ovarian cancer survival: A Norwegian population‐based cohort study. International Journal of Cancer. https://doi.org/10.1002/ijc.35348
Vancouver
Löfling LL, Støer NC, Sloan EK, Nafisi S, Fortner RT, Botteri E. Beta‐blockers and epithelial ovarian cancer survival: A Norwegian population‐based cohort study. International Journal of Cancer. 2025. doi:10.1002/ijc.35348
BibTeX
@article{Lfling2025,
author = {Löfling, Leif Lukas and Støer, Nathalie C and Sloan, Erica K and Nafisi, Sara and Fortner, Renée Turzanski and Botteri, Edoardo},
title = {Beta‐blockers and epithelial ovarian cancer survival: A Norwegian population‐based cohort study},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35348}
}
EUVIMED